Journal of medical economicsHumansParkinson DiseaseDrug CombinationsUnited KingdomAntiparkinson Agents
Foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson's disease (aPD): demonstration of savings from a societal perspective in the UK.
K Ray Chaudhuri, Lars Bergmann, Jonathan Belsey, Trishal Boodhna, Emanuele Leoncini
Published: 202510.1080/13696998.2025.2560759
Abstract
AIMS: In advanced Parkinson's disease (aPD), adequate 24-hour control of OFF-time may not be achievable using oral/transdermal therapies. Clinical trials of foslevodopa/foscarbidopa (LDp/CDP) demonstrate meaningful reductions in OFF-time and OFF-rela…
Preview only. Read the full abstract at the source